These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30217616)

  • 1. Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
    Heitner SB; Minnier J; Naher A; Van Woerkom RC; Ritts A; Ferencik M; Broberg C; Medvedova E; Silbermann R; Scott EC
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):796-802. PubMed ID: 30217616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity associated with bortezomib: A single-center experience.
    Gurram MK; Pulivarthi S; Ehresmann K; Mathew J
    J Cancer Res Ther; 2017; 13(6):961-963. PubMed ID: 29237959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process.
    Paraskevaidis IA; Makavos G; Tsirigotis P; Psarogiannakopoulos P; Parissis J; Gkirkas K; Pessach I; Ikonomidis I
    J Am Soc Echocardiogr; 2017 Nov; 30(11):1091-1102. PubMed ID: 28864152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
    Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
    Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
    [No Abstract]   [Full Text] [Related]  

  • 7. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Diagnosis of Cardiotoxicity in Patients Undergoing Chemotherapy for Acute Lymphoblastic Leukemia.
    Militaru A; Zus S; Cimpean AM; Iurciuc S; Matusz P; Iurciuc M; Lighezan D; Militaru M
    Anticancer Res; 2019 Jun; 39(6):3255-3264. PubMed ID: 31177176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Markers of the Acute Phase of Inflammation, Parameters of Blood Lipid Composition and Intracardiac Hemodynamics During Chemotherapy in Patients With Multiple Myeloma.
    Kardanova SA; Kirichenko YY; Bochkarnikova OV; Antyufeeva ON; Kochkareva YB; Vinogradova OY; Privalova EV; Ilgisonis IS; Belenkov YN
    Kardiologiia; 2022 Sep; 62(9):18-26. PubMed ID: 36206134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
    Leleu X; Kyriakou C; Vande Broek I; Murphy P; Bacon P; Lewis P; Gilet H; Arnould B; Petrucci MT
    Blood Cancer J; 2017 Mar; 7(3):e543. PubMed ID: 28304402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
    Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X
    Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
    Fradley MG; Groarke JD; Laubach J; Alsina M; Lenihan DJ; Cornell RF; Maglio M; Shain KH; Richardson PG; Moslehi J
    Br J Haematol; 2018 Jan; 180(2):271-275. PubMed ID: 29048105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma].
    Espinoza Zelada M; Befferman Cordova N; Ocqueteau Tachini M; Ramírez Villanueva P; Galleguillos M M; Sarmiento Maldonado M
    Medwave; 2015 Mar; 15(2):e6098. PubMed ID: 25831273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
    Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
    Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
    Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
    Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
    N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.
    de Waal EG; de Munck L; Hoogendoorn M; Woolthuis G; van der Velden A; Tromp Y; Vellenga E; Hovenga S
    Br J Haematol; 2015 Dec; 171(5):720-5. PubMed ID: 26358087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.